Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH – Get Rating) Director Floyd F. Petersen sold 491 shares of the company’s stock in a transaction dated Monday, April 3rd. The stock was sold at an average price of $37.72, for a total value of $18,520.52. Following the sale, the director now owns 85,117 shares of the company’s stock, valued […]
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH – Get Rating) saw a significant decline in short interest in the month of March. As of March 15th, there was short interest totalling 1,460,000 shares, a decline of 16.6% from the February 28th total of 1,750,000 shares. Currently, 4.1% of the shares of the company are sold short. Based on […]
Renaissance Technologies LLC increased its position in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH – Get Rating) by 6.6% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 433,800 shares of the company’s stock after purchasing an additional 26,900 shares during the […]
Lazard Asset Management LLC grew its holdings in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH – Get Rating) by 31.9% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 5,331 shares of the company’s stock after buying an additional 1,288 shares during the […]
Exchange Traded Concepts LLC reduced its position in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH – Get Rating) by 33.7% in the 3rd quarter, HoldingsChannel reports. The firm owned 36,017 shares of the company’s stock after selling 18,276 shares during the period. Exchange Traded Concepts LLC’s holdings in Amphastar Pharmaceuticals were worth $1,012,000 as of its […]